Janssen submits Genmab-developed drug for EMA approval

Shortly after applying for US marketing approval for drug candidate teclistamab, which is based on Genmab’s duobody platform, the US-based pharmaceutical firm has followed this up with a European application with the EMA.

Photo: Tuala Hjarnø / Genmab / PR

The European Medicines Council (EMA) has just received a new marketing authorization application for teclistamab, a treatment for relapsed or refractory multiple myeloma, which is a type of bone marrow cancer.

Janssen’s drug is based on Genmab’s Duobody platform and developed as a bone marrow cancer drug, and the two companies already have one successful partnership behind them on another cancer drug, Darzalex.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs